Tumor genomics, also known as cancer genomics, is an emerging sub-discipline in genomics, mainly through the high-throughput sequencing technology to associate genes with cancer. Tumor is a disease caused by the accumulation of DNA mutations that leads to an uncontrolled proliferation of cells and the formation of new organisms. The main goal of tumor genomics is to provide new methods for tumor diagnosis, tumor clinical outcome prediction and tumor target treatment by identifying new oncogenes or tumor suppressor genes.
LPI (LP Information)' newest research report, the “Tumor Genomics Industry Forecast” looks at past sales and reviews total world Tumor Genomics sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Genomics sales for 2023 through 2029. With Tumor Genomics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Genomics industry.
This Insight Report provides a comprehensive analysis of the global Tumor Genomics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Genomics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Genomics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Genomics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Genomics.
The global Tumor Genomics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Genomics players cover Abbott Laboratories, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, General Electric Company, Illumina, Inc. and Merck KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Genomics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Assays and Kits
Instrument
Segmentation by application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Tumor Genomics Market Size 2018-2029 2.1.2 Tumor Genomics Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Tumor Genomics Segment by Type 2.2.1 Assays and Kits 2.2.2 Instrument 2.3 Tumor Genomics Market Size by Type 2.3.1 Tumor Genomics Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Tumor Genomics Market Size Market Share by Type (2018-2023) 2.4 Tumor Genomics Segment by Application 2.4.1 Diagnostics and Monitoring 2.4.2 Drug Discovery and Development 2.4.3 Biomarker Discovery 2.5 Tumor Genomics Market Size by Application 2.5.1 Tumor Genomics Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Tumor Genomics Market Size Market Share by Application (2018-2023) 3 Tumor Genomics Market Size by Player 3.1 Tumor Genomics Market Size Market Share by Players 3.1.1 Global Tumor Genomics Revenue by Players (2018-2023) 3.1.2 Global Tumor Genomics Revenue Market Share by Players (2018-2023) 3.2 Global Tumor Genomics Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Tumor Genomics by Regions 4.1 Tumor Genomics Market Size by Regions (2018-2023) 4.2 Americas Tumor Genomics Market Size Growth (2018-2023) 4.3 APAC Tumor Genomics Market Size Growth (2018-2023) 4.4 Europe Tumor Genomics Market Size Growth (2018-2023) 4.5 Middle East & Africa Tumor Genomics Market Size Growth (2018-2023) 5 Americas 5.1 Americas Tumor Genomics Market Size by Country (2018-2023) 5.2 Americas Tumor Genomics Market Size by Type (2018-2023) 5.3 Americas Tumor Genomics Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Tumor Genomics Market Size by Region (2018-2023) 6.2 APAC Tumor Genomics Market Size by Type (2018-2023) 6.3 APAC Tumor Genomics Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Tumor Genomics by Country (2018-2023) 7.2 Europe Tumor Genomics Market Size by Type (2018-2023) 7.3 Europe Tumor Genomics Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Tumor Genomics by Region (2018-2023) 8.2 Middle East & Africa Tumor Genomics Market Size by Type (2018-2023) 8.3 Middle East & Africa Tumor Genomics Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Tumor Genomics Market Forecast 10.1 Global Tumor Genomics Forecast by Regions (2024-2029) 10.1.1 Global Tumor Genomics Forecast by Regions (2024-2029) 10.1.2 Americas Tumor Genomics Forecast 10.1.3 APAC Tumor Genomics Forecast 10.1.4 Europe Tumor Genomics Forecast 10.1.5 Middle East & Africa Tumor Genomics Forecast 10.2 Americas Tumor Genomics Forecast by Country (2024-2029) 10.2.1 United States Tumor Genomics Market Forecast 10.2.2 Canada Tumor Genomics Market Forecast 10.2.3 Mexico Tumor Genomics Market Forecast 10.2.4 Brazil Tumor Genomics Market Forecast 10.3 APAC Tumor Genomics Forecast by Region (2024-2029) 10.3.1 China Tumor Genomics Market Forecast 10.3.2 Japan Tumor Genomics Market Forecast 10.3.3 Korea Tumor Genomics Market Forecast 10.3.4 Southeast Asia Tumor Genomics Market Forecast 10.3.5 India Tumor Genomics Market Forecast 10.3.6 Australia Tumor Genomics Market Forecast 10.4 Europe Tumor Genomics Forecast by Country (2024-2029) 10.4.1 Germany Tumor Genomics Market Forecast 10.4.2 France Tumor Genomics Market Forecast 10.4.3 UK Tumor Genomics Market Forecast 10.4.4 Italy Tumor Genomics Market Forecast 10.4.5 Russia Tumor Genomics Market Forecast 10.5 Middle East & Africa Tumor Genomics Forecast by Region (2024-2029) 10.5.1 Egypt Tumor Genomics Market Forecast 10.5.2 South Africa Tumor Genomics Market Forecast 10.5.3 Israel Tumor Genomics Market Forecast 10.5.4 Turkey Tumor Genomics Market Forecast 10.5.5 GCC Countries Tumor Genomics Market Forecast 10.6 Global Tumor Genomics Forecast by Type (2024-2029) 10.7 Global Tumor Genomics Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Abbott Laboratories 11.1.1 Abbott Laboratories Company Information 11.1.2 Abbott Laboratories Tumor Genomics Product Offered 11.1.3 Abbott Laboratories Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Abbott Laboratories Main Business Overview 11.1.5 Abbott Laboratories Latest Developments 11.2 Agilent Technologies, Inc 11.2.1 Agilent Technologies, Inc Company Information 11.2.2 Agilent Technologies, Inc Tumor Genomics Product Offered 11.2.3 Agilent Technologies, Inc Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Agilent Technologies, Inc Main Business Overview 11.2.5 Agilent Technologies, Inc Latest Developments 11.3 Bio-Rad Laboratories, Inc. 11.3.1 Bio-Rad Laboratories, Inc. Company Information 11.3.2 Bio-Rad Laboratories, Inc. Tumor Genomics Product Offered 11.3.3 Bio-Rad Laboratories, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Bio-Rad Laboratories, Inc. Main Business Overview 11.3.5 Bio-Rad Laboratories, Inc. Latest Developments 11.4 Danaher Corporation 11.4.1 Danaher Corporation Company Information 11.4.2 Danaher Corporation Tumor Genomics Product Offered 11.4.3 Danaher Corporation Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Danaher Corporation Main Business Overview 11.4.5 Danaher Corporation Latest Developments 11.5 F. Hoffmann-La Roche Ltd 11.5.1 F. Hoffmann-La Roche Ltd Company Information 11.5.2 F. Hoffmann-La Roche Ltd Tumor Genomics Product Offered 11.5.3 F. Hoffmann-La Roche Ltd Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 F. Hoffmann-La Roche Ltd Main Business Overview 11.5.5 F. Hoffmann-La Roche Ltd Latest Developments 11.6 Fluidigm Corporation 11.6.1 Fluidigm Corporation Company Information 11.6.2 Fluidigm Corporation Tumor Genomics Product Offered 11.6.3 Fluidigm Corporation Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Fluidigm Corporation Main Business Overview 11.6.5 Fluidigm Corporation Latest Developments 11.7 General Electric Company 11.7.1 General Electric Company Company Information 11.7.2 General Electric Company Tumor Genomics Product Offered 11.7.3 General Electric Company Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 General Electric Company Main Business Overview 11.7.5 General Electric Company Latest Developments 11.8 Illumina, Inc. 11.8.1 Illumina, Inc. Company Information 11.8.2 Illumina, Inc. Tumor Genomics Product Offered 11.8.3 Illumina, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Illumina, Inc. Main Business Overview 11.8.5 Illumina, Inc. Latest Developments 11.9 Merck KGaA 11.9.1 Merck KGaA Company Information 11.9.2 Merck KGaA Tumor Genomics Product Offered 11.9.3 Merck KGaA Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Merck KGaA Main Business Overview 11.9.5 Merck KGaA Latest Developments 11.10 Myriad Genetics, Inc. 11.10.1 Myriad Genetics, Inc. Company Information 11.10.2 Myriad Genetics, Inc. Tumor Genomics Product Offered 11.10.3 Myriad Genetics, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Myriad Genetics, Inc. Main Business Overview 11.10.5 Myriad Genetics, Inc. Latest Developments 11.11 Pacific Biosciences of California, Inc. 11.11.1 Pacific Biosciences of California, Inc. Company Information 11.11.2 Pacific Biosciences of California, Inc. Tumor Genomics Product Offered 11.11.3 Pacific Biosciences of California, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Pacific Biosciences of California, Inc. Main Business Overview 11.11.5 Pacific Biosciences of California, Inc. Latest Developments 11.12 PerkinElmer 11.12.1 PerkinElmer Company Information 11.12.2 PerkinElmer Tumor Genomics Product Offered 11.12.3 PerkinElmer Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 PerkinElmer Main Business Overview 11.12.5 PerkinElmer Latest Developments 11.13 QIAGEN 11.13.1 QIAGEN Company Information 11.13.2 QIAGEN Tumor Genomics Product Offered 11.13.3 QIAGEN Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 QIAGEN Main Business Overview 11.13.5 QIAGEN Latest Developments 11.14 Siemens Healthineers AG 11.14.1 Siemens Healthineers AG Company Information 11.14.2 Siemens Healthineers AG Tumor Genomics Product Offered 11.14.3 Siemens Healthineers AG Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Siemens Healthineers AG Main Business Overview 11.14.5 Siemens Healthineers AG Latest Developments 11.15 Thermo Fisher Scientific Inc. 11.15.1 Thermo Fisher Scientific Inc. Company Information 11.15.2 Thermo Fisher Scientific Inc. Tumor Genomics Product Offered 11.15.3 Thermo Fisher Scientific Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Thermo Fisher Scientific Inc. Main Business Overview 11.15.5 Thermo Fisher Scientific Inc. Latest Developments 12 Research Findings and Conclusion